UCB presented 8 scientific abstracts at AD/PD 2025, including subgroup analysis of bepranemab's TOGETHER trial for Alzheimer's disease, the first anti-tau therapy showing clinical efficacy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.